Actuarial Patient Survival, Relapse, and LFS in Patients Randomized to Treatment With Busulfan or TBI
Parameter . | Busulfan (n = 88) . | TBI (n = 79) . | P . |
---|---|---|---|
Survival, 7 yr (%) | |||
All patients | 54 | 63 | .16 |
Early disease3-150 | 72 (n = 59) | 67 (n = 61) | .6 |
Advanced disease3-151 | 17 (n = 29) | 49 (n = 18) | .005 |
Relapse, 7 yr (%) | |||
All patients | 29 | 29 | |
Early disease | 21 | 27 | |
Advanced disease | 50 | 36 | |
LFS, 7 yr (%) | |||
All patients | 51 | 62 | .11 |
Early disease | 68 | 66 | |
Advanced disease | 17 | 49 | .009 |
AML | 59 (n = 37) | 56 (n = 32) | .7 |
ALL | 28 (n = 18) | 45 (n = 20) | .36 |
CML | 56 (n = 30) | 77 (n = 26) | .13 |
AML first remission | 80 (n = 25) | 58 (n = 26) | .24 |
ALL first remission | 27 (n = 11) | 36 (n = 11) | .86 |
CML first chronic phase | 72 (n = 22) | 83 (n = 24) | .42 |
Parameter . | Busulfan (n = 88) . | TBI (n = 79) . | P . |
---|---|---|---|
Survival, 7 yr (%) | |||
All patients | 54 | 63 | .16 |
Early disease3-150 | 72 (n = 59) | 67 (n = 61) | .6 |
Advanced disease3-151 | 17 (n = 29) | 49 (n = 18) | .005 |
Relapse, 7 yr (%) | |||
All patients | 29 | 29 | |
Early disease | 21 | 27 | |
Advanced disease | 50 | 36 | |
LFS, 7 yr (%) | |||
All patients | 51 | 62 | .11 |
Early disease | 68 | 66 | |
Advanced disease | 17 | 49 | .009 |
AML | 59 (n = 37) | 56 (n = 32) | .7 |
ALL | 28 (n = 18) | 45 (n = 20) | .36 |
CML | 56 (n = 30) | 77 (n = 26) | .13 |
AML first remission | 80 (n = 25) | 58 (n = 26) | .24 |
ALL first remission | 27 (n = 11) | 36 (n = 11) | .86 |
CML first chronic phase | 72 (n = 22) | 83 (n = 24) | .42 |